Updated phase 1 results of teclistamab, a B-cell maturation antigen (BCMA) <b>×</b> CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM).
Amrita Krishnan(City of Hope), Lixia Pei(Nanjing University of Chinese Medicine), Laura Rosiñol(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Jesús F. San Miguel(Clinica Universidad de Navarra), María‐Victoria Mateos(Hospital Clínico San Carlos), Niels W.C.J. van de Donk(Oncode Institute), Alfred L. Garfall(University of Pennsylvania), Lionel Karlin(Hôpital Lyon Sud), Manisha Bhutani(Carolinas Healthcare System), Ajai Chari(Icahn School of Medicine at Mount Sinai), Albert Oriol(Institut Català d'Oncologia), Raluca Verona(Centre Hospitalier Universitaire de Nantes), Arnob Banerjee(Johnson & Johnson (United States)), Suzette Girgis(Centre Hospitalier Universitaire de Nantes), Lotfi Benboubker, Tara Stephenson(Centre Hospitalier Universitaire de Nantes), Jenna D. Goldberg(Centre Hospitalier Universitaire de Nantes), Hareth Nahi(Karolinska University Hospital)
Cited by 15
Related Papers
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k